Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

The primary objectives are:

Phase 1 Part A

  • To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo
  • To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral shedding of SARS-CoV-2 Phase 2
  • To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral shedding of SARS-CoV-2
  • To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo in improving clinical status Phase 3
  • To evaluate and confirm the clinical efficacy of REGN10933+REGN10987 compared to placebo in improving clinical status

Site located at Providence Saint John’s Health Center and at Holy Cross Cancer Center – Mission Hills

Participate in a COVID-19 Clinical Trial

Learn More